GERM

Amplify Treatments, Testing and Advancements ETF
GERM

Delisted

GERM was delisted on the 5th of September, 2024.

Back to rankings

1 hedge funds and large institutions have $3.83K invested in Amplify Treatments, Testing and Advancements ETF in 2024 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 10 closing their positions.

Upgrade to unlock
New
Increased
Maintained
Reduced
Closed

less funds holding

Funds holding: →

less capital invested

Capital invested by funds: $ → $

less first-time investments, than exits

New positions opened: | Existing positions closed:

Holders
1
Holders Change
Holders Change %
% of All Funds
Holding in Top 10
–
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
Reduced
Closed
Calls
–
Puts
–
Net Calls
Net Calls Change

Top Buyers

No buyers this quarter

Top Sellers

1
-$850K
2
-$515K
3
-$27.3K
4
UBS Group
UBS Group
Switzerland
-$8.87K
5
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$6K
Name Holding Trade Value Shares
Change 		Change in
Stake
IA
1
IFP Advisors
Florida
$3.83K
Susquehanna International Group
2
Susquehanna International Group
Pennsylvania
–
Citadel Advisors
3
Citadel Advisors
Florida
–
FDCDDQ
4
Federation des caisses Desjardins du Quebec
Quebec, Canada
–
UBS Group
5
UBS Group
Switzerland
–
Bank of Montreal
6
Bank of Montreal
Ontario, Canada
–
Osaic Holdings
7
Osaic Holdings
Arizona
–
CHC
8
City Holding Co
West Virginia
–
TAM
9
Tucker Asset Management
Colorado
–
SPIA
10
Steward Partners Investment Advisory
New York
–
PCMC
11
Planning Capital Management Corporation
Pennsylvania
–